glesatinib + nivolumab

**Glesatinib + nivolumab** is an investigational combination therapy comprised of two agents: - **Glesatinib:** a small molecule, oral multi-kinase inhibitor targeting primarily mesenchymal epithelial transition factor (MET) and AXL kinases, implicated in certain cancers such as non-small cell lung cancer (NSCLC). It inhibits MET and AXL signaling pathways that contribute to tumor growth and resistance to therapy. - **Nivolumab:** a fully human monoclonal antibody targeting the programmed death 1 (PD-1) receptor. By blocking PD-1, nivolumab enhances T-cell mediated immune responses against tumor cells (immunotherapy/checkpoint inhibition). This combination is being investigated in clinical trials (e.g., Phase 2, NCT02954991) for patients with advanced NSCLC, aiming to capitalize on synergistic effects of targeted MET inhibition and immune checkpoint blockade[1][5].